BRIEF—Lilly lines up lung cancer data

Eli Lilly’s data at the American Society of Clinical Oncology annual meeting this year will provide results on its research in lung cancer.

The US pharma major will present the first results from RELAY, a Phase III study of ramucirumab in metastatic EGFR-mutated non-small cell lung cancer (NSCLC).

Lilly will also share early data from several investigational molecules as well as results from collaborative studies. This includes updated findings from the Phase III KEYNOTE-189 study of the pemetrexed-pembrolizumab-platinum chemotherapy combination, which has been established as the standard of care for the treatment of first-line metastatic non-squamous NSCLC.